Evaluation of Dual Versus Triple Therapy by Landmark Analysis in the RE-DUAL PCI Trial
Article 2021 en
Authors
BP
Benjamin E. Peterson
DB
Deepak L. Bhatt
PS
Philippe Gabríel Steg
Abstract
1 min read
In RE-DUAL PCI, in which patients in the dual-therapy arms were treated with aspirin for an average of only 1.6 days, there was early net clinical benefit with both doses of dabigatran dual therapy, without an increase in thrombotic events with dabigatran 150 mg. This could be helpful in the subset of patients with elevated risk for both bleeding and thrombotic events.
Christopher P. Cannon, Deepak L. Bhatt, Jonas Oldgren, Professor Gregory Lip, Stephen G. Ellis, Takeshi Kimura, Michael Mæng, Béla Merkely, Uwe Zeymer, Savion Gropper, Matias Nordaby, Eva Kleine, Ruth Harper, Jenny Manassie, James L. Januzzi, Jurriën M. ten Berg, Philippe Gabríel Steg, Stefan H. Hohnloser
Laura Mauri, P S Steg, Deepak L. Bhatt, Stefan H. Hohnloser, Matias Nordaby, Corinna Miede, Takeshi Kimura, Professor Gregory Lip, Jonas Oldgren, Jurriën M. ten Berg, Christopher P. Cannon
Jonas Oldgren, Philippe Gabríel Steg, Stefan H. Hohnloser, Professor Gregory Lip, Stephen G. Ellis, Takeshi Kimura, Matias Nordaby, Jurriën M. ten Berg, Deepak L. Bhatt, Christopher P. Cannon, Eva Kleine
Jonas Oldgren, Philippe Gabríel Steg, Stefan H. Hohnloser, Professor Gregory Lip, Stephen G. Ellis, Takeshi Kimura, Matias Nordaby, Jurriën M. ten Berg, Deepak L. Bhatt, Christopher P. Cannon, Eva Kleine
Discussion(0)
No comments yet. Be the first to comment.